HER-2 positivity is a high risk of recurrence of stage I gastric cancer
Background/Aims The treatment of gastric cancer remains unsatisfactory. We aimed to investigate the prognostic value of immunohistochemical staining in gastric cancer. Methods We analyzed 505 (279 early staged, 226 advanced-staged) gastric cancer tissues from patients who underwent radical gastric r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2021-11-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://www.kjim.org/upload/pdf/kjim-2020-243.pdf |
| _version_ | 1828146867970506752 |
|---|---|
| author | Seonhoo Kim Yeon-Ji Kim Woo Chul Chung |
| author_facet | Seonhoo Kim Yeon-Ji Kim Woo Chul Chung |
| author_sort | Seonhoo Kim |
| collection | DOAJ |
| description | Background/Aims The treatment of gastric cancer remains unsatisfactory. We aimed to investigate the prognostic value of immunohistochemical staining in gastric cancer. Methods We analyzed 505 (279 early staged, 226 advanced-staged) gastric cancer tissues from patients who underwent radical gastric resection between January 2014 and December 2016. Available surgical specimens immunohistochemically stained for p53, epidermal growth factor receptor (EGFR), human EGFR 2 (HER-2), E-cadherin, and Ki-67 were reviewed. We evaluated the association between positivity to various biomarkers and disease recurrence, disease-free survival, lymph node metastasis, and microscopic lymphovascular invasion. Results The median follow-up duration was 32.5 months (range, 7 to 70). Advanced gastric cancer cases showed high Ki-67 expression; other cases showed unremarkable expression. Concerning disease recurrence, lymphatic invasion, and disease-free interval, all biomarkers had no prognostic effects. HER-2-positive stage I gastric cancer tended to occur in old patients and in the upper one-third of the stomach (p = 0.01). HER-2 positivity was significantly correlated with disease recurrence (p = 0.01), lymphatic invasion (p = 0.03), and vascular invasion (p = 0.03) in stage I cases. Conclusions Only HER-2 was associated with the recurrence of stage I gastric cancer. HER-2-positive stage I gastric cancer requires additional therapy despite curative resection. |
| first_indexed | 2024-04-11T20:53:11Z |
| format | Article |
| id | doaj.art-e125d86b02dc4c33baa8a1e63e2a48ab |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-04-11T20:53:11Z |
| publishDate | 2021-11-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-e125d86b02dc4c33baa8a1e63e2a48ab2022-12-22T04:03:47ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482021-11-013661327133710.3904/kjim.2020.243170508HER-2 positivity is a high risk of recurrence of stage I gastric cancerSeonhoo Kim0Yeon-Ji Kim1Woo Chul Chung2Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, KoreaDepartment of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, KoreaDepartment of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, KoreaBackground/Aims The treatment of gastric cancer remains unsatisfactory. We aimed to investigate the prognostic value of immunohistochemical staining in gastric cancer. Methods We analyzed 505 (279 early staged, 226 advanced-staged) gastric cancer tissues from patients who underwent radical gastric resection between January 2014 and December 2016. Available surgical specimens immunohistochemically stained for p53, epidermal growth factor receptor (EGFR), human EGFR 2 (HER-2), E-cadherin, and Ki-67 were reviewed. We evaluated the association between positivity to various biomarkers and disease recurrence, disease-free survival, lymph node metastasis, and microscopic lymphovascular invasion. Results The median follow-up duration was 32.5 months (range, 7 to 70). Advanced gastric cancer cases showed high Ki-67 expression; other cases showed unremarkable expression. Concerning disease recurrence, lymphatic invasion, and disease-free interval, all biomarkers had no prognostic effects. HER-2-positive stage I gastric cancer tended to occur in old patients and in the upper one-third of the stomach (p = 0.01). HER-2 positivity was significantly correlated with disease recurrence (p = 0.01), lymphatic invasion (p = 0.03), and vascular invasion (p = 0.03) in stage I cases. Conclusions Only HER-2 was associated with the recurrence of stage I gastric cancer. HER-2-positive stage I gastric cancer requires additional therapy despite curative resection.http://www.kjim.org/upload/pdf/kjim-2020-243.pdfstomach neoplasmsrecurrencegenes erbb-2 |
| spellingShingle | Seonhoo Kim Yeon-Ji Kim Woo Chul Chung HER-2 positivity is a high risk of recurrence of stage I gastric cancer The Korean Journal of Internal Medicine stomach neoplasms recurrence genes erbb-2 |
| title | HER-2 positivity is a high risk of recurrence of stage I gastric cancer |
| title_full | HER-2 positivity is a high risk of recurrence of stage I gastric cancer |
| title_fullStr | HER-2 positivity is a high risk of recurrence of stage I gastric cancer |
| title_full_unstemmed | HER-2 positivity is a high risk of recurrence of stage I gastric cancer |
| title_short | HER-2 positivity is a high risk of recurrence of stage I gastric cancer |
| title_sort | her 2 positivity is a high risk of recurrence of stage i gastric cancer |
| topic | stomach neoplasms recurrence genes erbb-2 |
| url | http://www.kjim.org/upload/pdf/kjim-2020-243.pdf |
| work_keys_str_mv | AT seonhookim her2positivityisahighriskofrecurrenceofstageigastriccancer AT yeonjikim her2positivityisahighriskofrecurrenceofstageigastriccancer AT woochulchung her2positivityisahighriskofrecurrenceofstageigastriccancer |